Rise and shine. Another day is on the way. And we know that means - deadlines, meetings and coffee, or something else that stimulates the mind. Our preference, of course, is that cup of stimulation and our flavor today is seasonal Pumpkin Spice. Please excuse us while we indulge. Nonetheless, here are some interesting tidbits from around the world. Hope your day goes well and stay in touch...
Spain To Issue $7B In Bonds To Pay Pharma (Bloomberg News)
Stada Would Consider Merging With Drugmaker Or Biotech (Bloomberg News)
Bayer And Union Reach Tentative Deal On Contract (San Francisco Business Times)
Somaxon Says FDA Offers Path For Silenor OTC Approval (Dow Jones)
Abbott Sues Hospira Over Zemplar Patents (Crain's Chicago Business)
Merck KGgA And Ono Pharma To Develop MS Pill (Bloomberg News)
Supreme Court Rejects Mylan Appeal Of Anti-Trust Lawsuit (Bloomberg News)
AstraZeneca And Pfizer Sign Deal For Cancer Drug (Pharma Times)
Contraceptive Increases HIV Risk (MedPage Today)
EMA Develops New Vaccine Quality Guidelines (InPharma-Technologist)
Medicines Company Reaches Angiomax Patent Deal With Teva (Associated Press)
Baxter Sued By Family Over Contaminated Property (Associated Press)
Pfizer Signs Deal To Open Plant In Saudi Arabia (Bloomberg News)
Roche Shakes Up Roster Of Specialty Care PR Agencies (PR Week)
Florida Offers Incentives To Drugmaker To Build Plant (NWF Daily News)
EDITOR’S NOTE: Please check this post for updates throughout the morning
steaming coffee thx to dleggett on flickr
1 Comment
Ed, the contraceptive story is about Depo Provera, which is an injetable, not oral contraceptive. More importantly, DMPA has always been considereed as a "poor woman's contraception". Not surprisingly, one in five black teenagers using birth control in the US uses Depo-Provera, a far higher rate of use than for white teenagers. One activist, Dorothy Roberts, claims this is because black teenagers are disproportionately targeted for the least safe contraceptives. The increased incidence of HIV with this form of contraception, and thereby potentially in this population only serves to double the tragedy.
Relatedly, studies of DMPA in African woman have shown an increased incidence of chlamydia with DMPA use, and the product is still used globally despite experimental evidence demonstrating increased susceptibility to HIV in DMPA-treated primates.
http://www.msmagazine.com/apr01/roberts.html